We revealed a synergistic effect of PTK2B/FAK inhibition with commonly used therapeutics in FLT3-mutated AML cells and found this synergy to be particularly pronounced in cells with induced TKI-resistance. Here, PTK2B is linked to acute myeloid leukemia.